ATE480229T1 - Orale pharmazeutische zusammensetzung zur behandlung einer cox-2-vermittelten erkrankung - Google Patents

Orale pharmazeutische zusammensetzung zur behandlung einer cox-2-vermittelten erkrankung

Info

Publication number
ATE480229T1
ATE480229T1 AT06831741T AT06831741T ATE480229T1 AT E480229 T1 ATE480229 T1 AT E480229T1 AT 06831741 T AT06831741 T AT 06831741T AT 06831741 T AT06831741 T AT 06831741T AT E480229 T1 ATE480229 T1 AT E480229T1
Authority
AT
Austria
Prior art keywords
cox
pharmaceutical composition
oral pharmaceutical
treating
mediated disease
Prior art date
Application number
AT06831741T
Other languages
English (en)
Inventor
Gerard Soula
Florence Guimberteau
Original Assignee
Flamel Tech Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05300406A external-priority patent/EP1726300A1/de
Priority claimed from EP05300407A external-priority patent/EP1726301A1/de
Application filed by Flamel Tech Sa filed Critical Flamel Tech Sa
Application granted granted Critical
Publication of ATE480229T1 publication Critical patent/ATE480229T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06831741T 2005-05-24 2006-05-24 Orale pharmazeutische zusammensetzung zur behandlung einer cox-2-vermittelten erkrankung ATE480229T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US68377705P 2005-05-24 2005-05-24
US68377605P 2005-05-24 2005-05-24
EP05300406A EP1726300A1 (de) 2005-05-24 2005-05-24 Orale pharmazeutische Formulierung zur Vorbeugung und/oder Behandlung kardiovaskulärer und inflammatorischer Erkrankungen
EP05300407A EP1726301A1 (de) 2005-05-24 2005-05-24 Pharmazeutische Zusammensetzung zur Behandlung COX-2 vermittelter Krankheiten
PCT/IB2006/003659 WO2007036809A2 (en) 2005-05-24 2006-05-24 Novel acetylsalicylic acid formulations

Publications (1)

Publication Number Publication Date
ATE480229T1 true ATE480229T1 (de) 2010-09-15

Family

ID=42676680

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06831741T ATE480229T1 (de) 2005-05-24 2006-05-24 Orale pharmazeutische zusammensetzung zur behandlung einer cox-2-vermittelten erkrankung

Country Status (7)

Country Link
US (1) US20100009005A1 (de)
EP (1) EP1888045B1 (de)
JP (1) JP5232641B2 (de)
AT (1) ATE480229T1 (de)
CA (1) CA2609618C (de)
DE (1) DE602006016785D1 (de)
WO (1) WO2007036809A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2686874C (en) * 2007-05-09 2021-10-19 The Brigham And Women's Hospital, Inc Polymorphism in the apo(a) gene predict responsiveness to acetylsalicylic acid treatment
RU2630577C2 (ru) * 2008-12-04 2017-09-11 Чунси ЮЙ Композиции интенсивного проникновения и их применение
CA2763456C (en) 2009-05-27 2017-10-24 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate active agent compositions
US20110008432A1 (en) * 2009-06-25 2011-01-13 Pozen Inc. Method for Treating a Patient in Need of Aspirin Therapy
US11696894B2 (en) * 2013-12-17 2023-07-11 Celsprin Llc Sequential administration of partitioned absorption aspirin or active aspirin derivative and COX-2 inhibitor
US20170112857A1 (en) * 2015-10-27 2017-04-27 New Haven Pharmaceuticals, Inc. Extended Release Aspirin
WO2017184489A1 (en) * 2016-04-18 2017-10-26 Espero Pharmaceuticals Inc. Higher dose extended release aspirin
JP2019142860A (ja) * 2018-02-23 2019-08-29 ライオン株式会社 医薬組成物及び医薬製剤

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507276A (en) * 1982-08-20 1985-03-26 Bristol-Myers Company Analgesic capsule
AU591248B2 (en) * 1986-03-27 1989-11-30 Kinaform Technology, Inc. Sustained-release pharaceutical preparation
AU632602B2 (en) * 1989-08-02 1993-01-07 John David Arnold Method and preparation for reducing risk of myocardial infarction
US5409709A (en) * 1991-11-29 1995-04-25 Lion Corporation Antipyretic analgesic preparation containing ibuprofen
FR2704146B1 (fr) * 1993-04-19 1995-07-13 Cripdom Microcapsules d'acide acétylsalicylique à libération contrôlée.
AU1670995A (en) * 1994-01-28 1995-08-15 Cal International Limited A pharmaceutical product comprising a salicylate of an esterifiable ace-inhibitor
FR2725623A1 (fr) * 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
CN1277550A (zh) * 1997-09-11 2000-12-20 尼科梅德丹麦有限公司 非甾体抗炎药物(NSAIDs)的改进释放的复合型组合物
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP2004500358A (ja) * 1999-12-08 2004-01-08 ファルマシア　コーポレイション バイオアベイラビリティーが増加した固体状態のセレコキシブ
PL355391A1 (en) * 1999-12-22 2004-04-19 Pharmacia Corporation Sustained-release formulation of a cyclooxygenase-2 inhibitor
US7029701B2 (en) * 2000-09-11 2006-04-18 Andrx Pharmaceuticals, Llc Composition for the treatment and prevention of ischemic events
JP2004525897A (ja) * 2001-02-14 2004-08-26 グラクソ、ウェルカム、ソシエダッド、アノニマ 医薬処方
GB0124459D0 (en) * 2001-10-11 2001-12-05 Novartis Ag Organic compounds
EP1467714A1 (de) * 2002-01-07 2004-10-20 Pharmacia Corporation Wirkstoffmischung mit erhöhter auflösungsgeschwindigkeit
FR2837100B1 (fr) * 2002-03-18 2004-07-23 Flamel Tech Sa Comprimes a bases de microcapsules a liberation modifiee
JP2004188307A (ja) * 2002-12-11 2004-07-08 Japan Atom Energy Res Inst リン酸基を有するジルコニウム担持繊維状吸着材の合成方法、及びそれを用いたヒ素の除去
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer

Also Published As

Publication number Publication date
US20100009005A1 (en) 2010-01-14
JP2008542256A (ja) 2008-11-27
EP1888045B1 (de) 2010-09-08
JP5232641B2 (ja) 2013-07-10
DE602006016785D1 (de) 2010-10-21
CA2609618C (en) 2016-01-05
WO2007036809A3 (en) 2007-09-13
CA2609618A1 (en) 2007-04-05
WO2007036809A2 (en) 2007-04-05
EP1888045A2 (de) 2008-02-20

Similar Documents

Publication Publication Date Title
WO2007122580A3 (en) Compositions of phenylephrine useful for treatment of respiratory illness
EA200800064A1 (ru) Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
EA200870019A1 (ru) Лактамовые соединения и способы их применения
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
CY1114126T1 (el) Μεθοδοι θεραπειας μη-αλκοολικης στεατοηπατιτιδας (nash) χρησιμοποιωντας προϊοντα κυστεαμινης
EA201300242A1 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
EA200802166A1 (ru) Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
EA200701519A1 (ru) Живая аттенуированная ротавирусная вакцина для перорального введения
WO2007125501A3 (en) Liquid compositions comprising phenylephrine and acetaminophen and their use for the treatment of respiratory illness
CN108026053A8 (zh) 作为mIDH1抑制剂的稠合的咪唑类化合物
JP2009531457A5 (de)
ECSP17000643A (es) Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol.
MX2009008084A (es) Derivados de 5,6,7,8-tetrahidropteridina como inhibidores de hsp90.
NO20076405L (no) Anvendelse av 24-nor-UDCA
EA200901237A1 (ru) Применение димирацетама при лечении хронической боли
BRPI0911678B8 (pt) maleato de orvepitant cristalino anidro, composição farmacêutica compreedendo o dito maleato e uso do mesmo para o tratamento ou profilaxia de doenças do sistema nervoso central
ATE480229T1 (de) Orale pharmazeutische zusammensetzung zur behandlung einer cox-2-vermittelten erkrankung
BR112015019776A2 (pt) comprimidos de duplo uso oral em composições farmacêuticas de sais de sulfato e métodos de uso dos comprimidos
WO2006108679A3 (en) Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use to combat cancer
ATE534382T1 (de) Pharmazeutische zusammensetzungen von mit zuckeralkoholen zusammen mikronisiertem entacapon
EA200700413A1 (ru) Ариламинкетоны, способ их получения, фармацевтические композиции, содержащие их, и их применение
RU2006109966A (ru) Препарат "янтастим-с" для терапии и профилактики инфекционных заболеваний животных
ES2525376T3 (es) Composición farmacéutica comprendiendo amlodipino y ácido acetilsalicílico para uso en el tratamiento de hipertensión arterial sistémica
DE602006009511D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Hauterkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties